Skip to main content

Table 1 Arguments for and against requiring study partners in preclinical Alzheimer’s disease trials

From: Study partners should be required in preclinical Alzheimer’s disease trials

Against dyadic enrollment In favor of dyadic enrollment
• The requirement is a barrier to enrollment • Study partners may be necessary to ensure participant safety, assisting in overcoming distress related to biomarker disclosure
• Study partners are not needed to ensure adequate informed consent since participants are cognitively normal, autonomous decision makers • Individuals who lack a study partner may be at greatest risk for catastrophic reaction, including suicide
• The requirement may introduce novel risks related to confidentiality/privacy • The study partner can provide support that will mitigate stigma
• The requirement may introduce the risk of stigma to participants • The requirement may maximize participant retention
• The requirement may optimize data integrity
• Scales to measure patient function require study partners
• Involving study partners in trials may best instruct an as yet undefined practice